280 related articles for article (PubMed ID: 34985329)
21. Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatment.
Ulfhammer G; Edén A; Mellgren Å; Fuchs D; Zetterberg H; Hagberg L; Nilsson S; Yilmaz A; Gisslén M
AIDS; 2018 Sep; 32(15):2171-2178. PubMed ID: 30005007
[TBL] [Abstract][Full Text] [Related]
22. Nucleic acid oxidation is associated with biomarkers of neurodegeneration in CSF in people with HIV.
Ellis RJ; Moore DJ; Sundermann EE; Heaton RK; Mehta S; Hulgan T; Samuels D; Fields JA; Letendre SL
Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 33055205
[TBL] [Abstract][Full Text] [Related]
23. Increased cell-free mitochondrial DNA is a marker of ongoing inflammation and better neurocognitive function in virologically suppressed HIV-infected individuals.
Pérez-Santiago J; De Oliveira MF; Var SR; Day TRC; Woods SP; Gianella S; Mehta SR
J Neurovirol; 2017 Apr; 23(2):283-289. PubMed ID: 27921220
[TBL] [Abstract][Full Text] [Related]
24. A link between IL-23 and anti-CD4 autoantibody production in antiretroviral-treated HIV-infected individuals.
Luo Z; Li M; Mi F; Meng Z; Du G; Martin L; Liu H; Jin P; Stroncek D; Heath SL; Jiang W
J Virol; 2021 May; 95(11):. PubMed ID: 33731459
[TBL] [Abstract][Full Text] [Related]
25. Cerebrospinal Fluid and Plasma Lipopolysaccharide Levels in Human Immunodeficiency Virus Type 1 Infection and Associations With Inflammation, Blood-Brain Barrier Permeability, and Neuronal Injury.
Jiang W; Luo Z; Stephenson S; Li H; Di Germanio C; Norris PJ; Fuchs D; Zetterberg H; Gisslen M; Price RW
J Infect Dis; 2021 May; 223(9):1612-1620. PubMed ID: 33320240
[TBL] [Abstract][Full Text] [Related]
26. Anti-CD4 autoantibodies in immunological nonresponder people with HIV: cause of CD4 + T-cell depletion?
Muñoz-Muela E; Trujillo-Rodríguez M; Serna-Gallego A; Ruiz-Mateos E; Espinosa N; Roca-Oporto C; Benhnia MR; López-Cortés LF; Gutiérrez-Valencia A
AIDS; 2022 Jul; 36(9):1207-1214. PubMed ID: 35608119
[TBL] [Abstract][Full Text] [Related]
27. Neurocytoskeleton Proteins in Cerebrospinal Fluid of People With HIV-1 Subtypes B and C.
de Almeida SM; Ribeiro CE; Tang B; de Pereira AP; Rotta I; Vaida F; Letendre S; Potter M; Ellis RJ
J Acquir Immune Defic Syndr; 2020 Aug; 84(5):514-521. PubMed ID: 32692110
[TBL] [Abstract][Full Text] [Related]
28. Cerebrospinal fluid soluble CD30 elevation despite suppressive antiretroviral therapy in individuals living with HIV-1.
Peluso MJ; Thanh C; Prator CA; Hogan LE; Arechiga VM; Stephenson S; Norris PJ; Di Germanio C; Fuchs D; Zetterberg H; Deeks SG; Gisslén M; Price RW; Henrich TJ
J Virus Erad; 2020 Feb; 6(1):19-26. PubMed ID: 32175087
[TBL] [Abstract][Full Text] [Related]
29. The effect of plasma auto-IgGs on CD4
Luo Z; Zhou Z; Ogunrinde E; Zhang T; Li Z; Martin L; Wan Z; Wu H; Qin Z; Ou T; Zhang J; Ma L; Liao G; Heath S; Huang L; Jiang W
J Leukoc Biol; 2017 Dec; 102(6):1481-1486. PubMed ID: 29030391
[TBL] [Abstract][Full Text] [Related]
30. Soluble immune checkpoints as correlates for HIV persistence and T cell function in people with HIV on antiretroviral therapy.
Chiu CY; Schou MD; McMahon JH; Deeks SG; Fromentin R; Chomont N; Wykes MN; Rasmussen TA; Lewin SR
Front Immunol; 2023; 14():1123342. PubMed ID: 37056754
[TBL] [Abstract][Full Text] [Related]
31. Early Antiretroviral Therapy Is Associated with Lower HIV DNA Molecular Diversity and Lower Inflammation in Cerebrospinal Fluid but Does Not Prevent the Establishment of Compartmentalized HIV DNA Populations.
Oliveira MF; Chaillon A; Nakazawa M; Vargas M; Letendre SL; Strain MC; Ellis RJ; Morris S; Little SJ; Smith DM; Gianella S
PLoS Pathog; 2017 Jan; 13(1):e1006112. PubMed ID: 28046096
[TBL] [Abstract][Full Text] [Related]
32. Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden.
Spudich S; Gisslen M; Hagberg L; Lee E; Liegler T; Brew B; Fuchs D; Tambussi G; Cinque P; Hecht FM; Price RW
J Infect Dis; 2011 Sep; 204(5):753-60. PubMed ID: 21844301
[TBL] [Abstract][Full Text] [Related]
33. CSF neurofilament protein (NFL) -- a marker of active HIV-related neurodegeneration.
Abdulle S; Mellgren A; Brew BJ; Cinque P; Hagberg L; Price RW; Rosengren L; Gisslén M
J Neurol; 2007 Aug; 254(8):1026-32. PubMed ID: 17420923
[TBL] [Abstract][Full Text] [Related]
34. Following the Clues: Usefulness of Biomarkers of Neuroinflammation and Neurodegeneration in the Investigation of HTLV-1-Associated Myelopathy Progression.
Souza FDS; Freitas NL; Gomes YCP; Torres RC; Echevarria-Lima J; da Silva-Filho IL; Leite ACCB; de Lima MASD; da Silva MTT; Araújo AQC; Espíndola OM
Front Immunol; 2021; 12():737941. PubMed ID: 34764955
[TBL] [Abstract][Full Text] [Related]
35. Cerebrospinal fluid immune markers and HIV-associated neurocognitive impairments: A systematic review.
Williams ME; Stein DJ; Joska JA; Naudé PJW
J Neuroimmunol; 2021 Sep; 358():577649. PubMed ID: 34280844
[TBL] [Abstract][Full Text] [Related]
36. Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients.
Jessen Krut J; Mellberg T; Price RW; Hagberg L; Fuchs D; Rosengren L; Nilsson S; Zetterberg H; Gisslén M
PLoS One; 2014; 9(2):e88591. PubMed ID: 24523921
[TBL] [Abstract][Full Text] [Related]
37. Longitudinal decline of plasma neurofilament light levels after antiretroviral initiation in people living with HIV.
Ripamonti E; Edén A; Nilsson S; Sönnerborg A; Zetterberg H; Gisslén M
J Intern Med; 2023 Apr; 293(4):445-456. PubMed ID: 36443917
[TBL] [Abstract][Full Text] [Related]
38. Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection.
Kamat A; Lyons JL; Misra V; Uno H; Morgello S; Singer EJ; Gabuzda D
J Acquir Immune Defic Syndr; 2012 Jul; 60(3):234-43. PubMed ID: 22569268
[TBL] [Abstract][Full Text] [Related]
39. Cell-free mitochondrial DNA in CSF is associated with early viral rebound, inflammation, and severity of neurocognitive deficits in HIV infection.
Pérez-Santiago J; Schrier RD; de Oliveira MF; Gianella S; Var SR; Day TR; Ramirez-Gaona M; Suben JD; Murrell B; Massanella M; Cherner M; Smith DM; Ellis RJ; Letendre SL; Mehta SR
J Neurovirol; 2016 Apr; 22(2):191-200. PubMed ID: 26428514
[TBL] [Abstract][Full Text] [Related]
40. Soluble TLR2 and 4 concentrations in cerebrospinal fluid in HIV/SIV-related neuropathological conditions.
Mothapo KM; Ten Oever J; Koopmans P; Stelma FF; Burm S; Bajramovic J; Verbeek MM; Rikkert MGO; Netea MG; Koopman G; van der Ven AJ
J Neurovirol; 2017 Apr; 23(2):250-259. PubMed ID: 27882497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
